A Randomized, Double-Blind, Placebo-controlled Single-Dose Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Administration of Budigalimab in Adult People Living With HIV-1 (PLWH)
Latest Information Update: 24 Oct 2022
At a glance
- Drugs Budigalimab (Primary) ; Budigalimab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 14 Oct 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Previously healthy volunteers and patients are involved. Now subject type changed from healthy volunteers to patients only.
- 27 Apr 2022 Status changed from recruiting to active, no longer recruiting.